Abstract / Description of output
Thrombolytic therapy is licensed for use in highly selected patients with acute ischemic stroke. We aimed to model the health economic impact of limited use of thrombolytic therapy and to assess whether it was likely to be cost-effective when used more widely in the UK National Health Service (NHS).
Original language | English |
---|---|
Pages (from-to) | 1490-7 |
Number of pages | 8 |
Journal | Stroke |
Volume | 35 |
Issue number | 6 |
DOIs | |
Publication status | Published - 22 Mar 2004 |
Keywords / Materials (for Non-textual outputs)
- Acute Disease
- Brain Ischemia
- Cost-Benefit Analysis
- Great Britain
- Humans
- Models, Economic
- Recombinant Proteins
- Stroke
- Thrombolytic Therapy
- Tissue Plasminogen Activator